Magnetic Resonance Parkinsonism Index (MRPI) 2.0 may be used as a primary outcome measure in clinical trials in progressive supranuclear palsy (PSP).
Studies aiming to detect ≥20% treatment efficacy can potentially be performed over 2 years in progressive supranuclear palsy-Richardson syndrome (PSP-RS) and PSP-Parkinsonism (PSP-P) with a relatively small number of patients per treatment arm.
Why this matters
In recent years, MRPI has emerged as a highly accurate means of discriminating PSP from Parkinson’s disease (PD) or other parkinsonisms, as well as a way of predicting clinical evolution towards PSP phenotypes.
The investigations outlined in this study may impact future clinical trials in PSP-RS and PSP-P as the results suggest that MRPI 2.0 may be used as a primary outcome measure and inform on the optimal sample size for clinical trials.
Vuoi saperne di più?
Accedi o registrati per accedere a tutti i contenuti di Neurodiem.
Hai già un account? Accedi
International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.
No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.